SPECIAL NOTICE
65 -- Draft Request For Proposal for Advanced development and Food and Drug Adminstration approval of an Improved Nerve Agent Treatment System (INATS).
- Notice Date
- 1/9/2013
- Notice Type
- Special Notice
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- ACC-APG - Natick (SPS), ATTN: AMSRD-ACC-N, Natick Contracting Division (R and BaseOPS), Building 1, Kansas Street, Natick, MA 01760-5011
- ZIP Code
- 01760-5011
- Solicitation Number
- W911QY13R0018
- Archive Date
- 1/9/2014
- Point of Contact
- Richard Totten, 301-619-2446
- E-Mail Address
-
ACC-APG - Natick (SPS)
(richard.totten1@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- ANNOUNCEMENT OF DRAFT RFP: The Army Contracting Command Aberdeen Proving Ground (ACC-APG) Contracting Center, Natick Contracting Division, Natick, MA, in support of the Joint Project Manager for Chemical Biological Medical Systems (JPM CBMS) hereby issues a Draft Request for Proposal (DRFP) in advance of a Pre-Solicitation Conference for the Improved Nerve Agent Treatment System (INATS) procurement, to be held on or about 8 Feb 2013 in Frederick MD. This is a DRFP made available for comment prior to the Pre-Solicitation Conference. This is not a solicitation and CBMS is not requesting proposals at this time. The Department of Defense (DoD) is pursuing the advanced development of an INATS through to U.S. Food and Drug Administration (FDA) approval and optional delivery of procurement quantities. An improved nerve agent therapeutic and treatment system is necessary to counter the threat of conventional nerve agents as well as against nontraditional agents and emerging threats. To accomplish this goal, CBMS - Medical Identification and Treatment Systems (MITS) Joint Product Office intends to award a single contract to achieve all activities necessary to successfully deliver an FDA-approved autoinjector containing an improved oxime formulation and atropine, to replace the fielded Antidote Treatment Nerve Agent Autoinjector (ATNAA), containing the oxime 2-pralidoxime (2-PAM) and atropine. The contract will include options to provide for the delivery of Initial Operational Capability (IOC) and Full Operational Capability (FOC) quantity requirements. Additionally, the INATS development effort may include development of formulation enhancements that increase product efficacy (survival) against a broad spectrum of nerve agents as well as stability at operationally relevant temperatures and temperature extremes. This DRFP is released under announcement number W911QY-13-R-0018. Release of this DRFP is not a commitment by the Government to award a contract and the Government is not liable to reimburse any costs incurred by companies or entities that respond in any way to this DRFP or participate in the PreSolicitation Conference. Any information concerning the INATS Pre-Solicitation Conference will be amended to the DRFP and posted to the Federal Business Opportunities website at https://www.fbo.gov under announcement number W911QY-13-R-0018 and at http://www3.natick.army.mil/inats.html. CBMS will only accept questions regarding this DRFP in writing via e-mail to Mr. Richard Totten at richard.w.totten2.civ@mail.mil with the subject quote mark INATS DRFP Comments/Questions. quote mark The Government will not accept any questions after 5:00 pm EST, 08 February 2013. The Government may post responses to questions up until 5:00 pm EST 22 February 2013.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/notices/e62c977c4b3c0f7dabab2471d03c821b)
- Record
- SN02961913-W 20130111/130109234130-e62c977c4b3c0f7dabab2471d03c821b (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |